Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Target Price at $34.50

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) have been given a consensus rating of “Buy” by the six ratings firms that are presently covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $34.50.

A number of equities research analysts have recently weighed in on CAPR shares. Cantor Fitzgerald lifted their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. Piper Sandler started coverage on Capricor Therapeutics in a report on Monday, October 21st. They set an “overweight” rating and a $35.00 price target on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a report on Thursday, January 2nd.

Capricor Therapeutics Trading Up 2.6 %

CAPR opened at $15.95 on Friday. The business’s 50 day moving average is $14.15 and its 200-day moving average is $13.01. The stock has a market cap of $725.25 million, a PE ratio of -15.05 and a beta of 4.08. Capricor Therapeutics has a twelve month low of $3.52 and a twelve month high of $23.40.

Institutional Investors Weigh In On Capricor Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. raised its holdings in Capricor Therapeutics by 54.1% during the fourth quarter. Ameritas Investment Partners Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. grew its position in Capricor Therapeutics by 172.8% in the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after buying an additional 2,947 shares during the last quarter. Virtus ETF Advisers LLC acquired a new position in Capricor Therapeutics in the fourth quarter worth approximately $68,000. AlphaQuest LLC acquired a new position in Capricor Therapeutics in the fourth quarter worth approximately $78,000. Finally, New York State Common Retirement Fund grew its position in Capricor Therapeutics by 625.0% in the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock worth $80,000 after buying an additional 5,000 shares during the last quarter. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.